Company intelligence / Profile preview
Generex Biotechnology Corporation
- Ownership
- Public · GNBT
- Development stage
- Other
Overview
Generex developed several innovative technologies including an oral insulin spray (Oral‑lyn, approved in Ecuador), a HER2-targeting peptide vaccine (AE37, completed Phase IIb trials), wound healing products (Excellagen), point-of-care infectious disease diagnostics, and early-stage cell therapies. The company filed for Chapter 7 bankruptcy in April 2022 after years of financial difficulty. Asset sales were approved by court order in June 2022.
- Therapeutic areas
- GastroenterologyMetabolic DisordersRheumatologyImmunologyEndocrinologyDermatologyOtherOncologyInfectious Diseases
- Modalities
- Peptide vaccines (e.g., AE37)Oral insulin sprays (large molecule drugs)Cell therapy (Sertoli cells)Medical devices (wound care gels, surgical kits)
- Industry
- Biotech
Drug pipeline
12 assets11 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Generex Biotechnology Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Generex Biotechnology Corporation.